LONG-TERM SURVEY STUDY of the IMPACT of COVID-19 on SYSTEMIC AUTOIMMUNE DISEASES. LOW DEATH RATE DESPITE the INCREASED PREVALENCE of SYMPTOMATIC INFECTION. ROLE of PRE-EXISTING INTERSTITIAL LUNG DISEASE and ONGOING TREATMENTS in Annals of the Rheumatic Diseases
2022
AOU Città della Salute di Torino
Tipo pubblicazione
Conference Abstract
Autori/Collaboratori (84)Vedi tutti...
Bilia S
Clinical Immunology, University of Pisa, Pisa, Italy
Masini F
University of Campania, Luigi Vanvitelli, Napoli, Italy
Giannini D
Clinical Immunology, University of Pisa, Pisa, Italy
et alii...
Abstract
Background: Patients with autoimmune systemic diseases (ASDs) can be counted among frail populations as regards the predisposition to COVID-19 due to the frequent visceral organ involvement and comorbidities, as well as the ongoing immunomodulating treatments. Objectives: Our long-term multicenter telephone survey prospectively investigated the prevalence, prognostic factors, and outcomes of COVID-19 in Italian ASD patients during the frst 3 pandemic waves. Methods: A large series of 3,918 ASD patients (815 M, 3103 F; mean age 59±12SD years) was consecutively recruited at the 36 referral centers of COVID-19 & ASD Italian Study Group. In particular, ASD series encompassed the following conditions: rheumatoid arthritis (n: 981), psoriatic arthritis (n: 471), ankylosing spondylitis (n: 159), systemic sclerosis (n: 1,738), systemic lupus (172), systemic vasculitis (n: 219), and a miscellany of other ASDs (n: 178). The development of COVID-19 was recorded by means of telephone survey using standardized symptom-assessment questionnaire (1). Results: A signifcantly increased prevalence of COVID-19 (8.37% vs 6.49%; p<0.0001) was observed in our ASD patients, while the cumulative death rate revealed statistically comparable to the Italian general population (3.65% vs 2.95%; p: ns). In particular, among the 328 ASD patients complicated by COVID-19, 57 (17%) needed hospitalization, while mild-moderate manifestations were observed in the large majority of individuals (83%). In addition, 12/57 hospitalized patients died due to severe interstitial pneumonia and/or cardiovascular manifestations. Interestingly, a signifcantly higher COVID-19-related death rate was observed in systemic sclerosis patients compared to the Italian general population (6.29% vs 2.95%; p=0.018). Other adverse prognostic factors to develop COVID-19 were the patients' older age, male gender, pre-existing ASD-related interstitial lung involvement, and chronic steroid treatment. Conversely, patients t
Se sei accreditato in BVS-P effettua l'accesso per utilizzare i nostri servizi.
DOI : 10.1136/annrheumdis-2022-eular.4522
Keywords
drug therapy; systemic lupus erythematosus; systemic autoimmune disease; symptom assessment; rheumatoid arthritis; conference abstract; controlled study; coronavirus disease 2019; complication; chronic drug administration; attention; ankylosing spondylitis; SARS-CoV-2 vaccine; steroid; adult; aged; acetylsalicylic acid; disease modifying antirheumatic drug; telephone interview; systemic vasculitis; systemic sclerosis; endothelium injury; female; gender; health survey; hospital patient; hospitalization; human; interstitial lung disease; interstitial pneumonia; long term care; low drug dose; major clinical study; male; microangiopathy; middle aged; mortality; mortality rate; multicenter study; outcome assessment; pandemic; patient referral; prevalence; psoriatic arthritis; questionnaire;